(Q40609339)

22 September 2017

title

A phase II study of combined intravenous and subcutaneous interleukin-2 in malignant pleural mesothelioma (English)

1 reference

22 September 2017

Mulatero CW

1

1 reference

22 September 2017

Penson RT

2

1 reference

22 September 2017

Papamichael D

3

1 reference

22 September 2017

Gower NH

4

1 reference

22 September 2017

Evans M

5

1 reference

22 September 2017

Rudd RM

6

1 reference

22 September 2017

publication date

1 January 2001

1 reference

22 September 2017

1 reference

22 September 2017

volume

31

1 reference

22 September 2017

issue

1

1 reference

22 September 2017

page(s)

67-72

1 reference

Continuing increase in mesothelioma mortality in Britain.

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

The European mesothelioma epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Analysis of current trends in United States mesothelioma incidence

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Chemotherapy in malignant pleural mesothelioma. A review.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

A review of chemotherapy trials for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Asbestos fibres inhibit the in vitro activity of ymphokine-activated killer (LAK) cells from healthy individualsand patients with malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibers but can be restored by recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Interleukin-2 toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2800%2900157-4

7 January 2021

10.1016/S0169-5002(00)00157-4

Identifiers

DOI

1 reference

22 September 2017

1 reference